Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

immunity · Mechanism Report

Does isolated Borrelia IgM prove ongoing infection?

Isolated Borrelia-specific IgM does not prove ongoing infection.

PlausibleSeptember 23, 20267 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Borrelia-specific IgM can persist after infection and can produce false-positive or cross-reactive results, so isolated IgM reactivity does not establish ongoing infection.

laying out figure…
0 of 3 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says Borrelia-specific IgM can persist after a past infection and can also be false-positive or cross-reactive. The mechanism framing shows that both persistent antibody reactivity and nonspecific assay reactivity can lead to an isolated IgM result, which is not enough on its own to establish active infection.

Verified conclusion

The claim is strongly supported: Borrelia-specific IgM can persist after resolved infection and can be nonspecifically reactive, so an isolated IgM result is not proof of ongoing infection.

Clinical and serologic evidence

  • In long-term Lyme follow-up using two-tier ELISA/Western blot testing, IgM remained positive 10–20 years after treated illness in 4/40 (10%) people with prior early Lyme disease and 6/39 (15%) with prior Lyme arthritis. Antibody persistence therefore cannot distinguish active infection from immunologic memory after eradication.
  • For Lyme disease, CDC guidance limits IgM interpretation to symptoms of ≤30 days. After this interval, isolated IgM should be disregarded because persistent and false-positive IgM reactions are common. Serology is not a test of cure, treatment failure, or microbiologic persistence.
  • Diagnosis requires a compatible syndrome plus validated standard or modified two-tier testing—not a single reactive assay, antigen, or IgM band.

Cross-reactivity and mechanisms

  • False-positive IgM can arise through nonspecific antibody binding and cross-reactivity, documented with EBV/infectious mononucleosis, syphilis, relapsing-fever Borrelia, and rheumatoid arthritis.
  • Individual immunoblot antigens are not diagnostic in isolation. The 41-kDa FlaB/p41 band is particularly nonspecific, occurring in 43% of healthy controls. CDC IgM immunoblot criteria require reactivity to at least 2 of 3 designated bands; isolated VlsE1, OspC, or BmpA reactivity is insufficient.
  • In relapsing fever, serology may cross-react between Borrelia species. PCR can help during acute illness, but a negative result does not exclude infection because sensitivity depends on timing, specimen, syndrome, and antibiotic exposure.

Bottom line

  • Isolated Borrelia IgM indicates neither ongoing infection nor a need for treatment by itself. Its meaning depends on symptom duration, compatible clinical features, exposure probability, and properly performed confirmatory testing.

References

  1. Clinical Testing and Diagnosis for Lyme Disease - CDC — cdc.gov ↗
  2. Suggested Reporting Language, Interpretation and Guidance for Lyme Disease Serologic Testing Results — cdc.gov ↗
  3. Appropriate laboratory testing in Lyme disease — ccjm.org ↗
  4. Antibody Cross-Reactivity in Serodiagnosis of Lyme Disease — pmc.ncbi.nlm.nih.gov ↗
  5. Clinical Guidance for Soft Tick Relapsing Fever (STRF) - CDC — cdc.gov ↗
  6. Tick borne relapsing fever - a systematic review and analysis of the ... — journals.plos.org ↗
  7. AAN/ACR/IDSA 2020 Guidelines for the Prevention, Diagnosis and ... — idsociety.org ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Unsupported4 sourcesDoes a positive Anaplasma IgM alone diagnose active anaplasmosis?→Plausible13 sourcesCan gliotoxin and mycophenolic acid alter immune processes without proving neural autoimmunity?→